Status:
WITHDRAWN
Pharmacokinetics and Safety of Transdermal Megestrol Acetate
Lead Sponsor:
Milton S. Hershey Medical Center
Conditions:
Cachexia
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Rationale: Megestrol acetate (Megace®) is a progestin analog that is FDA approved for the palliative treatment of breast and endometrial carcinoma. It is also commonly used as an appetite stimulant, p...
Detailed Description
Study Population: Patients of any age who are already receiving oral Megace as an appetite stimulant. Patients must have an indwelling IV catheter in order to draw drug levels. Major Inclusion \& Exc...
Eligibility Criteria
Inclusion
- Patients of any age who are already receiving oral Megace as an appetite stimulant.
- Patients must have an indwelling IV catheter in order to draw drug levels.
Exclusion
- Known hypersensitivity to the transdermal vehicle.
- Taking any other medicine that would interfere with the Megace assay.
- Weight less than 10 kg.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00163072
Start Date
October 1 2005
End Date
December 1 2012
Last Update
October 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hershey Medical Center
Hershey, Pennsylvania, United States, 17033